First-in-human clinical trial of personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma

Lymphoplasmacytic lymphoma (LPL) is an incurable low-grade B-cell lymphoma of the bone marrow. Despite a cumulative risk of progression, there is no approved therapy for patients in the asymptomatic phase. We conducted a first-in-human clinical trial of a novel therapeutic DNA idiotype neoantigen va...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwak, Larry, Szymura, Szymon, Wang, Lin, Zhang, Tiantian, Cha, Soung-chul, Dong, Zhenyuan, Anderson, Aaron, Oh, Elizabeth, Lee, Vincent, Wang, Zhe, Parshottham, Sapna, Rao, Sheetal, Olsem, Jasper, Crumpton, Brandon, Lee, Hans, Manasanch, Elisabet, Neelapu, Sattva, Thomas, Sheeba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543432/
https://www.ncbi.nlm.nih.gov/pubmed/37790486
http://dx.doi.org/10.21203/rs.3.rs-3315017/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543432/
https://www.ncbi.nlm.nih.gov/pubmed/37790486
http://dx.doi.org/10.21203/rs.3.rs-3315017/v1

Ejemplares similares